UnitedHealth Group has reached an agreement to acquire 80% stake in healthcare services provider American Health Network in order to expand its business.

Both companies involved in the transaction are based in the US.

The target company will become a part of the acquirer company’s OptumCare division, following the completion of the transaction.

Private equity (PE) firms Bain Capital Private Equity and Cinven Partners have reached an agreement over a takeover offer to acquire the entire outstanding shares of German-based pharmaceutical and healthcare company Stada Arzneimittel for approximately €4.1bn ($4.34bn).

“German healthcare company Fresenius SE & Co. has announced its plans to acquire Akorn, which has a current market value of approximately $3.7bn.”

The offer price represents an enterprise value of €5.3bn ($5.61bn).

The PE firms have agreed to pay €66 ($69.87) a share, which includes 2016 dividend of €0.72 ($0.76) a share proposed by Stada Arzneimittel’s management board, to the target company’s shareholders.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

German healthcare company Fresenius SE & Co. has announced its plans to acquire US-based pharmaceutical company Akorn, which has a current market value of approximately $3.7bn.

The acquisition is expected to complement the acquirer company’s Kabi medicines division.